GlassScriptPhysician profile
James A Bentley
NPI 1902894199
$1,899.35
in general payments reported to CMS, 2019-2025
23 companies · $133 in 2025
The $133 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $274 · 2020: $339 · 2021: $202 · 2022: $258 · 2023: $356 · 2024: $338 · 2025: $133.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $827.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $826.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $452.65 | 2022-2025 | Alphagan P, Lumigan, Durysta |
| Allergan, INC. | $218.16 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $156.81 | 2020-2022 | |
| Alcon Vision LLC | $155.46 | 2019-2024 | Rocklatan, Clareon, Simbrinza |
| Biotissue Holdings INC. | $145.97 | 2020-2024 | |
| Aerie Pharmaceuticals, INC. | $104.87 | 2019-2021 | |
| Ani Pharmaceuticals, INC. | $87.66 | 2022-2024 | Purified Cortrophin Gel |
| Thea Pharma INC. | $80.31 | 2023-2025 | Iyuzeh |
| Sun Pharmaceutical Industries INC. | $66.69 | 2020-2025 | |
| Kala Pharmaceuticals, INC. | $65.49 | 2019-2021 | |
| Ocular Therapeutix, INC. | $50.66 | 2019 | |
| Bausch & Lomb Americas INC. | $46.45 | 2024-2025 | Vyzulta, Miebo |
| Rayner Intraocular Lenses Limited | $43.40 | 2022-2023 | Omidria, Rayone Spheric, Rayone Emv |
| Oyster Point Pharma, INC. | $40.27 | 2022 | |
| Novartis Pharmaceuticals Corporation | $24.68 | 2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $23.22 | 2021 | |
| Eyepoint US, INC. | $22.09 | 2019 | |
| Carl Zeiss Meditec USA, INC. | $21.93 | 2024 | Callisto Eye |
| Johnson & Johnson Surgical Vision, INC. | $21.03 | 2019 | |
| Mallinckrodt Enterprises LLC | $20.89 | 2019 | |
| Notal Vision, INC. | $18.95 | 2019 | |
| Halozyme INC | $18.90 | 2022 | |
| Tearlab Corp | $12.81 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Bentley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.